doValue (DOV) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Apr, 2026Executive summary
Achieved or exceeded all 2025 business plan targets, with EBITDA ex-NRI reaching €217 million (32% YoY growth, 37% margin), and net income ex-NRI more than tripling to €25 million.
Free cash flow was €76 million, above guidance, with recurring FCF at €93 million and net leverage improved to 2.0x.
New business intake reached €14.5 billion (1.8x target), with cumulative new business in 2024-2025 above €24 billion and a robust pipeline supporting visibility into 2026.
Major M&A transactions included near-complete Gardant integration and pending coeo acquisition, both expected to reshape growth and digital transformation.
Solid financial structure with no refinancing needs before 2030 and a liquidity buffer of €277 million.
Financial highlights
Gross revenue grew 21% YoY to €580 million; net revenue also up 21% to €524 million.
EBITDA ex-NRI margin improved to 37% (up 3 p.p. YoY); operating expenses ex-NRI rose 14.6% to €307 million.
Net income ex-NRI increased to €25 million from €7 million YoY, despite higher financing costs.
Free cash flow before debt repayment was €76 million, up €118 million YoY; recurring FCF at €93 million.
Net leverage at 2.0x, down from 2.4x YoY, in line with guidance.
Outlook and guidance
2026 targets: consolidated revenue ~€800 million, EBITDA ex-NRI ~€300 million, leverage ~2.2x pre-dividends.
Free cash flow target of €90 million for 2026, with positive working capital contribution expected.
18-month commercial pipeline of ~€50 billion, diversified across geographies and asset classes.
Dividend payout to be proposed at the high end of the 50%-70% range, consistent with group policy.
Focus on coeo integration, digital platform rollout, and accelerated AI adoption.
Latest events from doValue
- EBITDA beat expectations in H1 2024 as the Gardant deal advanced and transformation continued.DOV
Q2 20242 Feb 2026 - Exceeded €8bn new GBV, confirmed guidance, and advanced the Gardant acquisition.DOV
Q3 202415 Jan 2026 - 2024 targets exceeded with €10bn new GBV, €165m EBITDA ex-NRI, and improved leverage.DOV
Q4 20241 Dec 2025 - Record revenue and EBITDA growth, strong cash flow, and digital expansion via coeo acquisition.DOV
Q2 202523 Nov 2025 - Revenues up 46% YoY, EBITDA ex-NRI doubled, and new business GBV exceeded targets.DOV
Q1 202521 Nov 2025 - Transformative €350M acquisition accelerates digital growth, diversification, and EPS accretion.DOV
M&A Announcement16 Nov 2025 - EBITDA ex-NRI up 43% YoY, net income ex-NRI doubled, and FY guidance confirmed.DOV
Q3 202512 Nov 2025 - Gardant acquisition propels doValue toward €130bn+ GBV and greater revenue diversification.DOV
Corporate Presentation13 Jun 2025 - doValue's Gardant acquisition creates a €130bn GBV credit management leader in Southern Europe.DOV
M&A Presentation13 Jun 2025